Showing results (21-30 of 108) with videos related to

Sort By:
Pageof 11
Neoplasia (New York, N.Y.)|June 2, 2009
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancerYa-Ting Yang, Curt Balch, Samuel K Kulp, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|August 25, 2016
Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancerLauren E Himmel, Maryam B Lustberg, A Courtney DeVries, et al.
Plos One|October 17, 2012
Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agentShuo Wei, Po-Chen Chu, Hsiao-Ching Chuang, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cellsMei-Chuan Chen, Chun-Han Chen, Hsiao-Ching Chuang, et al.
Anticancer Research|March 16, 2004
The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathwayJiahua Jiang, Yasuro Sugimoto, Suling Liu, et al.
BMC Veterinary Research|December 19, 2012
Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell linesJason I Couto, Misty D Bear, Jiayuh Lin, et al.
Journal of Medicinal Chemistry|April 4, 2012
Development of a novel class of glucose transporter inhibitorsDasheng Wang, Po-Chen Chu, Chia-Ning Yang, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2009
Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensisHao-Chieh Chiu, Jian Yang, Shilpa Soni, et al.
Molecular Pharmacology|August 27, 2009
Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinomaHany A Omar, Aaron M Sargeant, Jing-Ru Weng, et al.
Molecular Cancer Therapeutics|April 17, 2008
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitorShu-Chuan Weng, Yoko Kashida, Samuel K Kulp, et al.
Pageof 11